Verified peer comparison
BMY vs LLY
Bristol-Myers Squibb Company compared with Eli Lilly and Company. This page compares both source-verified company profiles and does not introduce an unverified price target.
BMY
Bristol-Myers Squibb Company
$189.43
- Open
- --
- High
- --
- Low
- --
- Market Cap
- --
LLY
Eli Lilly and Company
$782.10
- Open
- --
- High
- --
- Low
- --
- Market Cap
- --
Company-specific comparison
Business exposure
BMY: Pharmaceuticals
LLY: Pharmaceuticals
Upside lens
BMY: Opdivo, Camzyos, Sotyktu, Breyanzi and Reblozyl can offset part of the mature-brand decline. Improved manufacturing and site expansion can increase patient throughput for Breyanzi and Abecma. Clinical and regulatory milestones can refresh the portfolio across oncology, immunology and neuroscience.
LLY: obesity drug adoption and pipeline expansion
Risk lens
BMY: Generic and biosimilar competition can accelerate declines in major legacy products. Clinical setbacks or slow launches could leave growth products unable to replace lost legacy revenue. Acquisition-related debt can constrain flexibility while integration and milestone payments consume cash.
LLY: supply constraints and valuation expectations
Verified sources
Bristol Myers Squibb Reports First Quarter 2026 Financial ResultsBristol-Myers Squibb Company · earningsVerified
Bristol-Myers Squibb Company Investor RelationsBristol-Myers Squibb Company · companyVerified
Fetched: 7/12/2026, 12:00:00 AM UTC
Open original sourceBristol Myers Squibb SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified
Lilly Reports First-Quarter 2026 Financial ResultsEli Lilly and Company · earningsVerified
Eli Lilly Investor RelationsEli Lilly and Company · companyVerified
Fetched: 7/11/2026, 12:00:00 AM UTC
Open original sourceForm 10-Q for the Quarter Ended March 31, 2026Eli Lilly and Company · filingVerified
LLY editorial research profileAlphaVue Research · editorialVerified
Fetched: 7/11/2026, 12:00:00 AM UTC